Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma

Why did Trump demand ending the filibuster? How is the government shutdown affecting SNAP benefits? What drives Amazon's latest stock surge? Why is Nexperia halting chip supplies to China? How is AI spending impacting tech earnings? What caused Disney channels to vanish on YouTube TV? Why are air traffic controller shortages delaying flights?

Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma

gsk.com/en-gb/media/press-releases/blenrep-approved-by-us-fda-for-use-in-treatment-of-relapsedrefractory-multiple-myeloma

Significant unmet need for patients requires new and novel treatments1
- DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free survival in 3L+ indicated population versus a daratumumab-based triplet2
- Blenrep is the only anti-BCMA accessible in the…

This story appeared on gsk.com, 2025-10-23 22:25:04.424000.